Literature DB >> 35228335

Race-Ethnic Disparities in Rates of Declination of Thrombolysis for Stroke.

Scott J Mendelson1, Shuaiqi Zhang1, Roland Matsouaka1, Ying Xian1, Shreyansh Shah1, Barbara L Lytle1, Nicole Solomon1, Lee H Schwamm1, Eric E Smith1, Jeffrey L Saver1, Gregg Fonarow1, Jane Holl1, Shyam Prabhakaran1.   

Abstract

BACKGROUND AND OBJECTIVES: Prior regional or single-center studies have noted that 4% to 7% of eligible patients with acute ischemic stroke (AIS) decline IV tissue plasminogen activator (tPA). We sought to determine the prevalence of tPA declination in a nationwide registry of patients with AIS and to investigate differences in declination by race/ethnicity.
METHODS: We used the Get With The Guidelines-Stroke registry to identify patients with AIS eligible for tPA and admitted to participating hospitals between January 1, 2016, and March 28, 2019. We compared patient demographics and admitting hospital characteristics between tPA-eligible patients who received and those who declined tPA. Using multivariable logistic regression, we determined patient and hospital factors associated with tPA declination.
RESULTS: Among 177,115 tPA-eligible patients with AIS at 1,976 sites, 6,545 patients (3.7%) had tPA declination as the sole documented reason for not receiving tPA. Patients declining treatment were slightly older, were more likely to be female, arrived more often at off-hours and earlier after symptom onset, and were more likely to present to Primary Stroke Centers. Compared with non-Hispanic White, non-Hispanic Black race/ethnicity was independently associated with increased (adjusted odds ratio [aOR] 1.21, 95% CI 1.11-1.31), Asian race/ethnicity with decreased (aOR 0.72, 95% CI 0.58-0.88), and Hispanic ethnicity (any race) with similar odds of tPA declination (OR 0.98, 95% CI 0.86-1.13) in multivariable analysis. DISCUSSION: Although the overall prevalence of tPA declination is low, eligible non-Hispanic Black patients are more likely and Asian patients less likely to decline tPA than non-Hispanic White patients. Reducing rates of tPA declinations among non-Hispanic Black patients may be an opportunity to address disparities in stroke care.
© 2022 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35228335      PMCID: PMC9052571          DOI: 10.1212/WNL.0000000000200138

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Gender differences in stroke care decision-making.

Authors:  Moira K Kapral; Jennifer Devon; Anne-Luise Winter; Julie Wang; Anne Peters; Susan J Bondy
Journal:  Med Care       Date:  2006-01       Impact factor: 2.983

2.  Eligibility and rate of treatment for recombinant tissue plasminogen activator in acute ischemic stroke using different criteria.

Authors:  Poyin Huang; Gim-Thean Khor; Chun-Hung Chen; Ruey-Tay Lin; Ching-Kuan Liu
Journal:  Acad Emerg Med       Date:  2011-03       Impact factor: 3.451

3.  Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study.

Authors:  Amie W Hsia; Dorothy F Edwards; Lewis B Morgenstern; Jeffrey J Wing; Nina C Brown; Regina Coles; Sarah Loftin; Andrea Wein; Sara S Koslosky; Sabiha Fatima; Brisa N Sánchez; Ali Fokar; M Chris Gibbons; Nawar Shara; Annapurni Jayam-Trouth; Chelsea S Kidwell
Journal:  Stroke       Date:  2011-06-30       Impact factor: 7.914

4.  Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.

Authors:  Gregg C Fonarow; Xin Zhao; Eric E Smith; Jeffrey L Saver; Mathew J Reeves; Deepak L Bhatt; Ying Xian; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

5.  Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Salvador Cruz-Flores; Alejandro Rabinstein; Jose Biller; Mitchell S V Elkind; Patrick Griffith; Philip B Gorelick; George Howard; Enrique C Leira; Lewis B Morgenstern; Bruce Ovbiagele; Eric Peterson; Wayne Rosamond; Brian Trimble; Amy L Valderrama
Journal:  Stroke       Date:  2011-05-26       Impact factor: 7.914

6.  Racial disparities in refusal of stroke thrombolysis in Chicago.

Authors:  Scott J Mendelson; Neelum T Aggarwal; Christopher Richards; Kathleen O'Neill; Jane L Holl; Shyam Prabhakaran
Journal:  Neurology       Date:  2018-01-03       Impact factor: 9.910

7.  Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity.

Authors:  S C Johnston; L H Fung; L A Gillum; W S Smith; L M Brass; J H Lichtman; A N Brown
Journal:  Stroke       Date:  2001-05       Impact factor: 7.914

8.  Patient refusal of thrombolytic therapy for suspected acute ischemic stroke.

Authors:  F S Vahidy; M H Rahbar; A P Lal; J C Grotta; S I Savitz
Journal:  Int J Stroke       Date:  2012-12-11       Impact factor: 5.266

Review 9.  Call to Action: Structural Racism as a Fundamental Driver of Health Disparities: A Presidential Advisory From the American Heart Association.

Authors:  Keith Churchwell; Mitchell S V Elkind; Regina M Benjamin; April P Carson; Edward K Chang; Willie Lawrence; Andrew Mills; Tanya M Odom; Carlos J Rodriguez; Fatima Rodriguez; Eduardo Sanchez; Anjail Z Sharrief; Mario Sims; Olajide Williams
Journal:  Circulation       Date:  2020-11-10       Impact factor: 29.690

10.  Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers.

Authors:  Hugo J Aparicio; Brendan G Carr; Scott E Kasner; Michael J Kallan; Karen C Albright; Dawn O Kleindorfer; Michael T Mullen
Journal:  J Am Heart Assoc       Date:  2015-10-14       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.